Compare BioNTech SE - ADR (BNTX) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Home Depot Inc — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Home Depot Inc trades at $337.71 (market cap $336.77B). The key difference: Home Depot Inc is far larger — about 14.7× BioNTech SE - ADR's market cap, and Home Depot Inc pays a 2.76% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | HD | |
|---|---|---|
Market Cap | $22.86B | $336.77B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $423.42 |
52-Week Low | $83.89 | $297.51 |
Enterprise Value | $6.53B | $398.32B |
Dividend Yield | — | 2.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
Home Depot (HD) trades at $337.11, down 1.8% on the day, with a bearish technical signal and mixed earnings history. The stock shows strong profitability with a net margin of 8.41% and ROE of 128.38%, but faces margin compression and weak big-ticket demand. Recent news highlights institutional selling and concerns over rising mortgage rates impacting home improvement spending.
The outlook is cautious due to near-term headwinds, but analyst consensus remains bullish with a $370.59 price target. Risks include housing market sensitivity and competitive pressures, while opportunities lie in Pro segment growth and dividend stability. Long-term prospects depend on economic resilience and execution against margin challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
